759 related articles for article (PubMed ID: 18054441)
1. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
Har-Noy M; Slavin S
Med Hypotheses; 2008; 70(6):1186-92. PubMed ID: 18054441
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
[TBL] [Abstract][Full Text] [Related]
4. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
[TBL] [Abstract][Full Text] [Related]
5. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
Anderson LD; Petropoulos D; Everse LA; Mullen CA
Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
[TBL] [Abstract][Full Text] [Related]
8. Cancer therapy based on a mechanism of action for controlling the immune system and the resulting patent portfolio.
Goswitz VC; Sawicki ZP
Recent Pat Endocr Metab Immune Drug Discov; 2013 Jan; 7(1):1-10. PubMed ID: 23215852
[TBL] [Abstract][Full Text] [Related]
9. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
Zöller M; Matzku S
Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease.
Yoshida Y; Hirano T; Son G; Iimuro Y; Imado T; Iwasaki T; Fujimoto J
Am J Physiol Gastrointest Liver Physiol; 2007 Dec; 293(6):G1114-23. PubMed ID: 17761834
[TBL] [Abstract][Full Text] [Related]
11. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
[TBL] [Abstract][Full Text] [Related]
12. Graft versus neuroblastoma reaction is efficiently elicited by allogeneic bone marrow transplantation through cytolytic activity in the absence of GVHD.
Ash S; Gigi V; Askenasy N; Fabian I; Stein J; Yaniv I
Cancer Immunol Immunother; 2009 Dec; 58(12):2073-84. PubMed ID: 19437016
[TBL] [Abstract][Full Text] [Related]
13. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic bone marrow transplantation: relation between chimaerism and immunity.
Vossen J
Verh K Acad Geneeskd Belg; 1998; 60(2):111-43; discussion 143-5. PubMed ID: 9703764
[TBL] [Abstract][Full Text] [Related]
15. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
16. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
17. Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects.
Ueha S; Murai M; Yoneyama H; Kitabatake M; Imai T; Shimaoka T; Yonehara S; Ishikawa S; Matsushima K
J Leukoc Biol; 2007 Jan; 81(1):176-85. PubMed ID: 17053165
[TBL] [Abstract][Full Text] [Related]
18. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
[TBL] [Abstract][Full Text] [Related]
19. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation.
Teshima T; Mach N; Hill GR; Pan L; Gillessen S; Dranoff G; Ferrara JL
Cancer Res; 2001 Jan; 61(1):162-71. PubMed ID: 11196155
[TBL] [Abstract][Full Text] [Related]
20. Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting.
Le NT; Chen BJ; Chao NJ
Cytotherapy; 2005; 7(2):126-33. PubMed ID: 16040391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]